Drug Trial Radar · NCT06081894
A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
500
Planned (sponsor's estimate)
Start
Aug 31, 2023
Primary completion
Aug 31, 2026
Study completion Nov 2026
Sponsor
- Lead sponsor
- CytokineticsIndustry
- Sponsor type
- Industry
- Collaborators
- Sanofi; Bayer
- First posted
- Oct 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial will study the effects of aficamten (versus placebo) on the quality of life, exercise capacity, and clinical outcomes of patients with non-obstructive hypertrophic cardiomyopathy.
Conditions
- Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Interventions
AficamtenDrug
Oral Tablet
PlaceboDrug
Oral Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-CSS)Time frame: Baseline to Week 36
- Change in pVO2Time frame: Baseline to Week 36
Locations
180 sites in 20 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
UC San Diego Health - Sulpizio Cardiovascular Center
La Jolla, California
Keck Medical Center of USC (Outpatient Clinic)
Los Angeles, California
Cedars-Sinai Medical Center (Smidt Heart Institute)
Los Angeles, California
UCLA Medical Center Cardiovascular Clinic
Los Angeles, California
University of California San Francisco
San Francisco, California
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Torrance, California
Yale New Haven Hospital
New Haven, Connecticut
MedStar Washington Hospital Center
Washington D.C., District of Columbia
Holy Cross Medical Group - Cardiology Associates
Fort Lauderdale, Florida
Investigational Drug Services, AdventHealth Orlando
Orlando, Florida
Emory Clinic
Atlanta, Georgia
Piedmont Heart Institute (CPET)
Fayetteville, Georgia
The Queen's Medical Center-Punchbowl
Honolulu, Hawaii
Northwestern University
Evanston, Illinois
Ascension St. Vincent
Indianapolis, Indiana
University of Iowa Hospitals and Clinics
Iowa City, Iowa
The University of Kansas Medical Center
Kansas City, Kansas
MedStar Union Memorial Hospital
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts
Lahey Hospital & Medical Center
Burlington, Massachusetts
Michigan Medicine
Ann Arbor, Michigan
Henry Ford Hospital
Detroit, Michigan
M Health Fairview University of Minnesota Medical Center - East Bank
Minneapolis, Minnesota
Mayo Clinic
Rochester, Minnesota
Saint Luke's Hospital of Kansas City
Kansas City, Missouri
Morristown Medical Center
Morristown, New Jersey
Northwell Health North Shore University Hospital
Manhasset, New York
NYU Langone Health
New York, New York
Weill Cornell Medicine
New York, New York
Mount Sinai Hospital
New York, New York
Columbia University Medical Center/New York Presbyterian Hospital
New York, New York
Westchester Medical Center
Valhalla, New York
Sanger Heart & Vascular Institute - HCM Clinic
Charlotte, North Carolina
The Lindner Research Center at The Christ Hospital
Cincinnati, Ohio
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Cleveland Clinic
Cleveland, Ohio
Providence St. Vincent Medical Center
Portland, Oregon
Oregon Health & Science University
Portland, Oregon
Showing 40 of 180 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.